Table 3 The enriched pathways of the responsive gene modules of VEGF stimulated HUVECs identified by different methods.
Pathway | ClustEx Meet/Min (z-score) | jActiveModules Meet/Min (z-score) | GXNA Meet/Min (z-score) | FoldChange_2.0 Meet/Min (z-score) |
|---|---|---|---|---|
Chronic myeloid leukemia | 0.25(6.20), 1 a | 0.19(5.32), 2 | 0.07(0.72), 4 | 0.19(3.67), 3 |
TGF-beta signaling pathway | 0.23(5.88), 1 | 0.14(3.40), 2 | 0.04(-0.53), 4 | 0.14(2.20), 3 |
Adherens junction | 0.22(4.74), 1 | 0.10(1.73), 3 | 0.12(2.50), 2 | 0.12(1.23), 4 |
Pancreatic cancer | 0.19(3.99), 2 | 0.18(4.76), 1 | 0.06(0.13), 4 | 0.17(2.76), 3 |
Neurodegenerative Diseases | 0.24(3.75), 1 | 0.12(1.57), 2 | 0.03(-0.61), 4 | 0.12(0.81), 3 |
Focal adhesion | 0.13(3.66), 1 | 0.08(1.72), 2 | 0.07(1.16), 4 | 0.11(1.71), 3 |
Cell cycle | 0.16(3.51), 2 | 0.16(5.02), 1 | 0.01(-1.89), 4 | 0.05(-1.27), 3 |
Long-term potentiation | 0.19(3.47), 1 | 0.10(1.52), 2 | 0.05(-0.05), 4 | 0.08(0.13), 3 |
Wnt signaling pathway | 0.14(3.24), 1 | 0.06(0.35), 2 | 0.04(-0.74), 3 | 0.05(-1.03), 4 |
Prostate cancer | 0.16(3.15), 2 | 0.15(3.74), 1 | 0.06(0.38), 4 | 0.10(0.72), 3 |
SNARE interactions in vesicular transport | 0.23(3.11), 1 | 0.00(-1.43), 4 | 0.00(-1.38), 3 | 0.06(-0.31), 2 |
Renal cell carcinoma | 0.17(3.09), 1 | 0.09(1.44), 3 | 0.08(0.93), 4 | 0.14(1.90), 2 |
Notch signaling pathway | 0.21(3.04), 2 | 0.27(5.60), 1 | 0.03(-0.54), 4 | 0.12(0.89), 3 |
Acute myeloid leukemia | 0.17(2.74), 2 | 0.17(3.73), 1 | 0.06(0.15), 4 | 0.13(1.43), 3 |
Endometrial cancer | 0.17(2.47), 2 | 0.17(3.42), 1 | 0.06(0.29), 4 | 0.10(0.58), 3 |
Dorso-ventral axis formation | 0.22(2.43), 2 | 0.22(3.11), 1 | 0.09(0.71), 3 | 0.09(0.06), 4 |
Apoptosis | 0.13(1.95), 2 | 0.04(-0.77), 3 | 0.03(-1.19), 4 | 0.19(3.63), 1 |
Fc epsilon RI signaling pathway | 0.09(0.57), 4 | 0.08(0.70), 3 | 0.17(4.40), 1 | 0.15(2.23), 2 |
Small cell lung cancer | 0.06(-0.54), 3 | 0.11(2.27), 2 | 0.04(-0.70), 4 | 0.20(4.31), 1 |